# Study of the Combination of a Tyrosine Kinase Inhibitor (STI571) and a Pegylated Human Recombinant Interferon alfa2b (PEGINTRON)

> **NCT00511121** · PHASE2 · TERMINATED · sponsor: **University of Bologna** · enrollment: 5 (—)

## Conditions studied

- Chronic Myeloid Leukemia

## Interventions

- **DRUG:** STI571 and PEG INTRON

## Key facts

- **NCT ID:** NCT00511121
- **Lead sponsor:** University of Bologna
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2001-04
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 5 (—)
- **Last updated:** 2007-08-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00511121

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00511121, "Study of the Combination of a Tyrosine Kinase Inhibitor (STI571) and a Pegylated Human Recombinant Interferon alfa2b (PEGINTRON)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00511121. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*